Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

Impact · against what's priced in

Ondine Biomedical removes immediate liquidity risk by securing a runway into 2028, though the market remains cautious regarding future dilution for the US launch. Galliford Try gains a material pipeline opportunity via the Pagabo National Framework.

OBI+0.40: No priced-in read yet
In context: The £10 million fundraise eliminates the immediate threat of insolvency and provides a cash runway to reach the mid-2027 NDA submission target.
Read from the article alone

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

biotech▲14%
healthcare
GFRD
OBI
broker rating
fda
fundraise
nda
pharma
regulatory

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

What matters in this story

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

What matters in this story

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

How each ticker is affected

Track these names every morning.

Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review

IXICO shares jump 19% as revenue growth and order book strengthen

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Oracle stock's next big AI opportunity may have nothing to do with data centres

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

What matters in this story

Next reads from the same story arc

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Ondine Biomedical fundraise gives runway into 2028 as NDA submission moves closer

What matters in this story

Next reads from the same story arc

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

How each ticker is affected

Track these names every morning.

Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review

IXICO shares jump 19% as revenue growth and order book strengthen

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

Oracle stock's next big AI opportunity may have nothing to do with data centres